EUCTR2008-005999-28-FR进行中（未招募）不适用
PHASE I-II TRIAL OF ERLOTINIB IN HIGHER RISK MYELODYSPLASTIC SYNDROME - GFM-Erlotinib-08
Groupe Francophone des Myélodysplasies (GFM)0 个研究点开始时间: 2009年12月28日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria
- •1.Diagnosis of MDS according to the WHO classification, but also including RAEB in transformation as defined by the FAB classification (that is patients with up to 30% of blasts in the bone marrow);
- •2.Higher-risk MDS as defined by a IPSS score >1 (IPSS: Int-2 or High);
- •3.Life expectancy > 3 months;
- •4.Percentage of bone marrow blasts >10 and <30%;
- •5.Ineligible for or having failed intensive chemotherapy and ineligible for or having failed previous therapy with a hypomethylating agent;
- •6.Age = 18 years;
- •7.Written informed consent;
- •8.Patient must understand and voluntarily sign consent form;
- •9.Patient must be able to adhere to the visit schedule as outlined in the study and follow protocol requirements;
- •10.ECOG performance status between 0-2 at the time of screening;
- •11.Females of childbearing potential (defined as a sexually mature woman who has not undergone a hysterectomy or who is not naturally postmenopausal for at least 24 consecutive months, that is who has had menses at any time during the preceeding 24 consecutive months) have to have a negative pregnancy test;
- •12.Adequate contraceptive methods should be carried out by all patients during therapy and for at least 2 weeks after completing therapy.
- •13.No existing contra-indication to treatment with erlotinib.
- •14.Health insurance.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria
- •1.Serum creatinine = 1.5 x the upper limit of normal, or creatinine clearance =60 mL/min;
- •2.Concomitant treatment with NSAIDS, warfarin, omeprazole, ranitidine or inducers (i.e. rifampicin, phenytoin; carbamazepin) or inhibitors (i.e. ketoconazole, ciprofloxacin, clarithromycine, voriconazole) of CYP3A4;
- •3.Inadequate liver function as defined by a serum bilirubine =1.5 x the upper limit of normal (except in the case of confirmed moderate unconjugated hyperbilirubinemia due to intramedullary hemolysis, as observed frequently in MDS), and/or ASAT/ALAT/GGT levels =2 x the upper limit of normal;
- •4.Known HIV-positivity;
- •5.Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he or she participates in the study;
- •6.Vitamine B12 or folate deficiency;
- •7.Pregnant or lactating females;
- •8.Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within the 28 days preceeding study entry;
- •9.Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast), unless the subject has been disease-free for =3 years;
- •10.Patients with a history of corneal disorders or another active ophthalmic disorder, active infections or other concomitant serious and uncontrolled medical conditions.
- •11.History of interstitial lung disease or any active pulmonary disease.
- •Patients with a history of myeloproliferative syndrome or LMMC.
研究者
相似试验
已完成
1 期
Erlotinib in Higher Risk Myelodysplastic SyndromeMyelodysplastic SyndromeNCT01085838Groupe Francophone des Myelodysplasies30
进行中（未招募）
1 期
A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR - Study of targeted Erlotinib treatment for Non-small cell lung cancerStage IIIb/IV non-small cell lung cancer (NSCLC) tumours that over-express EGFRMedDRA version: 9.1 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2007-001264-72-GBOxford Radcliffe Hospitals NHS Trust35
进行中（未招募）
不适用
Phase II trial of Erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer. - tarcevapancreasPatients with unresectable advanced or metastatic pancreatic cancerMedDRA version: 6.1Level: PTClassification code 10033609EUCTR2006-001238-41-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
已完成
2 期
A phase II study of Erlotinib for patients previously treated non-small cell lung cancer with epidermal growth factor receptor mutationon-small cell lung cancerJPRN-UMIN000004563Fukushima Medical University, cancer center26
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29